Prima BioMed Ltd (PBMD) : 4 brokerage houses believe that Prima BioMed Ltd (PBMD) is a Strong Buy at current levels. Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 4 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.
Prima BioMed Ltd (PBMD) : Average target price received by Prima BioMed Ltd (PBMD) is $5 with an expected standard deviation of $1.41. The most aggressive target on the stock is $6, whereas the most downbeat target is $3. 4 financial analysts are currently covering the stock.
Shares of Prima Biomed Ltd. appreciated by 2.14% during the last five trading days but lost 2.5% on a 4-week basis. Prima Biomed Ltd. has dropped 17.5% during the last 3-month period . Year-to-Date the stock performance stands at -24.74%. Prima BioMed Ltd (NASDAQ:PBMD): stock turned positive on Tuesday. Though the stock opened at $0.84, the bulls momentum made the stock top out at $0.8638 level for the day. The stock recorded a low of $0.84 and closed the trading day at $0.858, in the green by 1.83%. The total traded volume for the day was 26,592. The stock had closed at $0.8426 in the previous days trading.
Prima BioMed Limited is an Australia-based biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. The Company focuses on cancer immunotherapy research. The Companys main pipeline of products is based on the LAG-3 immune control mechanism, which plays a role in the regulation of the T cell immune response. The Companys product is a T cell immunostimulatory factor (APC activator), IMP321, for cancer chemoimmunotherapy, which has completed Phase II trials. In addition, it has developed infrastructure for a cell-based therapy manufacturing platform and taken CVac, an autologous dendritic cell-based product through Phase II clinical trials for ovarian cancer patients in remission. The Companys other products include IMP731 for autoimmune disease, and IMP701 for cancer and chronic infectious disease.